C&EN: COVER STORY - GENERIC DRUGS -
[Cached Version]
Published on: 10/15/2002
Last Visited: 10/15/2002
Likewise, Cambrex Corp.'s Italian subsidiary Profarmaco in Paullo, Italy, has brought in innovator business to complement its roster of 60 generic APIs, according to Paolo Russolo, president of Cambrex's generic pharmaceuticals business unit.
But Italian companies are also taking steps to shore up the generics business.Russolo notes that after the law went into effect, Profarmaco started scouting for a U.S. plant where it could carry out trial-scale production.Instead, in 1994 it was acquired by Cambrex, which has since built the needed facilities at its U.S. sites.
...
After a dry spell, Russolo says, Profarmaco is getting back into the new generics game.It is investing $2.5 million in R&D at the Paullo site and has been developing synthesis routes for APIs that go off patent in 2005 and beyond."After 2005, we will be ready with a huge list of products," he says.
[Previous Story] [Next Story]
Top
Chemical & Engineering NewsCopyright © 2002 American Chemical Society